Alto Neuroscience climbs on FDA's 'fast track' tag for schizophrenia drug

Alto Neuroscience

03/10/2025 12:54

** Shares of drug developer Alto Neuroscience ANRO.N rise 10% to $4.93 premarket

** Co says its experimental drug, ALTO-101, got the U.S. FDA's "fast track" designation, to help improve thinking and memory in people with schizophrenia

** FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical need

** Co is testing ALTO-101 in a mid-stage trial and said earlier studies showed it helped healthy volunteers think more clearly

** ALTO-101 works by boosting a brain chemical that helps with learning and memory and is delivered through the skin, co says

** As of last close, stock up 4% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))